公司资料
ProKidney 股价、新闻与催化剂
- 股票代码:
- PROK
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.61 USD (+13.38%)
收盘价
最后更新: 2026年8月21日
390M USD
市值
股价为何变动
As of Aug 21, 2026, PROK closed up 13.4% at $1.61. No new same-company headline was identified in the current news window.
公司概览
Regenerative Kidney Medicine
ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation.
Rilparencel
Rilparencel, also known as REACT, is a proprietary autologous cell therapy manufactured from a patient's own kidney cells. The product has Regenerative Medicine Advanced Therapy designation and is designed to restore or stabilize kidney function through repeat image-guided injections.
Phase 3 Development
The Phase 3 REGEN-006, or PROACT 1, study evaluates rilparencel against a sham procedure. Its design supports an accelerated-approval analysis based on annualized eGFR slope and a longer confirmatory analysis based on kidney-function decline, dialysis, transplantation, or renal and cardiovascular death.
未来催化剂
- Completion of full enrollment in the Phase 3 REGEN-006 study in the second half of 2026.
- Topline results from the accelerated-approval efficacy analysis of REGEN-006 in the second quarter of 2027.
- Topline results from the confirmatory composite time-to-event analysis of REGEN-006 in the second half of 2029.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。